Today's health technology highlights include a nationwide rollout of virtual physical therapy, insights into the FDA's evolving stance on AI regulations, and other notable industry updates.

Edison Scientific is collaborating with investment firm Population Health Partners to utilize AI agents for accelerating drug discovery and development in the biotechnology sector. This partnership aims to harness cutting-edge AI technology to create new biotechnological solutions and enhance the efficiency of pharmaceutical research and development.

Portugal's National Health Service has entered into an agreement with digital health firm Sword Health to implement AI-assisted virtual physical therapy across the country, aiming to enhance patient care and accessibility.

Clive Meanwell, chairman of Population Health Partners, once skeptical about AI, now views it as a powerful catalyst in advancing biotechnologies designed for improving population health.

Sten H. Vermund and Patricia J. Kissinger highlight the growing energy consumption of artificial intelligence technologies as an emerging risk to public health. They emphasize the need to recognize this impact and propose actionable solutions to mitigate AI's strain on vital health resources.

In this edition of STAT Health Tech, discover how a biotech startup transformed the disappointment of a failed clinical trial into a breakthrough AI model, alongside other industry insights.

Which of the emerging obesity drugs has the potential to truly lead the market? Which company recently made headlines with a record-breaking IPO? And what decisions might the Food and Drug Administration be making about these treatments?

Wearable devices generate vast amounts of health data, but until now, this information has largely remained outside clinical settings. Recent advancements by companies like Oura and Whoop are starting to bridge this gap, potentially integrating wearable-generated health data into clinical practice for better patient monitoring and outcomes.

Although the number of prescription drug shortages in the U.S. decreased by 23% last year, a recent analysis highlights ongoing systemic problems affecting the availability of many medicines.

William Padula highlights a critical gap in healthcare: while cures exist, the real challenge lies in establishing systems to finance and effectively deliver these expensive treatments.